Skip to content

Study · Observational study · 2020

1 result

Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors.

Grenader T, Pavel ME, Ruszniewski PB, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Truong Thanh XM, Caplin ME

Anti-cancer drugs1 Mar 2020Cited by 6 (Europe PMC)

PMID31977567 (opens in a new tab)PMCIDPMC7028287 (opens in a new tab)DOI10.1097/cad.0000000000000909 (opens in a new tab)PepBankPUB-31977567
Read at sourcePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients with advanced enteropancreatic NETs, lanreotide's therapeutic effect versus placebo did not depend on NLR.

    In plain wordsIn patients with advanced NETs, lanreotide's effect versus placebo did not depend on NLR.

    Peptide
    Lanreotide
    Outcome
    No significant changeTreatment effect by NLR
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Tumor growth · Cancer
    Studied dose
    120 mgAs given in this study (human).

    Measurements

    P value for treatment effect by NLR
    > 0.1
    lanreotide versus placebo, across NLR subgroups

    Source sentences

    Summary
    The therapeutic effect of lanreotide autogel/depot 120 mg was independent of NLRs (P > 0.1).
    1 context sentence
    Summary · context
    In the randomized double-blind CLARINET study (NCT00353496; EudraCT 2005-004904-35), the somatostatin analog lanreotide autogel/depot increased progression-free survival (PFS) compared with placebo in patients with inoperable or metastatic intestinal and pancreatic NETs (grades 1-2, Ki-67 < 10%).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.